EverQuote Trades Above 200-Day SMA: Time to Buy the Stock?

EverQuote (EVER) is exhibiting a short-term bullish trend, trading above its 200-day SMA, yet its 7.7% year-to-date gain significantly underperforms the industry and broader market. Despite an expensive valuation with a price-to-book of 4.94x, the company projects robust growth, with 2025 EPS and revenue estimates up 47.7% and 28.9% respectively, driven by increasing consumer quote requests and high capital efficiency (ROE 36.9%). However, rising operational costs, intense market competition, and potential regulatory pressures present significant headwinds, leading analysts to suggest a cautious approach given the current risk-reward profile.

Analysis

EverQuote, Inc. (EVER) presents a mixed profile characterized by strong growth prospects offset by a premium valuation and significant operational headwinds. On a technical basis, the stock is trading above its 200-day simple moving average, signaling a short-term bullish trend. However, its year-to-date share price gain of 7.7% substantially underperforms its industry (12.6%), sector (20.4%), and the S&P 500 (20.3%). The company's valuation is a key concern, with a price-to-book ratio of 4.94x, more than double the industry average of 2.05x. This premium is supported by robust growth forecasts, including a Zacks Consensus Estimate for a 47.7% year-over-year increase in 2025 EPS and a 28.9% rise in revenue, further bolstered by recent upward analyst revisions. Fundamentally, growth is driven by rising consumer quote requests and an expected normalization in the auto insurance market. EverQuote also demonstrates superior capital efficiency, with a return on equity of 36.9% and a return on invested capital of 36.3%, far exceeding industry averages. Nevertheless, these positive factors are tempered by rising expenses, intense competition, and potential regulatory risks that could impact future profitability.

Key Decisions for Investors

• Investors should weigh the company's strong forward growth projections, including a 47.7% estimated EPS increase for 2025 and a 43.2% potential upside to analyst price targets, against its current premium valuation and significant year-to-date market underperformance.
• It is critical to monitor upcoming financial reports for the company's ability to manage rising operating costs and defend its market share against intense competition, as these are the primary risks to the growth narrative.
• Given the stock is trading 21.6% below its 52-week high despite positive technical signals, a cautious or hold-rated stance is warranted until there is clearer evidence that operational momentum can overcome valuation and competitive pressures.